An interesting finding from this study is that the decreased reabsorption capacity of SGLT transporters is a significant factor contributing to the reduced efficacy of SGLT2 inhibitors in patients with T2DM and renal insufficiency. This evidence concerns the gene SLC5A2 and Renal insufficiency.